Prescriber Scope of Practice for General Psychiatry in California

If you’re a psychiatrist or psychiatric nurse practitioner wondering whether you can legally prescribe ADHD medications like Adderall through telehealth—you’re not alone. This question has been at the top of every mental health provider’s mind since COVID-era telehealth flexibilities took hold, and for good reason: the rules have been in constant flux.

Here’s the reality as of early 2026: Yes, you can still prescribe controlled substances including Schedule II stimulants via telehealth—at least through December 31, 2026. But the regulatory landscape is shifting, and what’s legal today may require different compliance steps next year when the DEA finalizes permanent telemedicine rules.

This isn’t a simple yes-or-no answer. The ability to prescribe Adderall, benzodiazepines, or buprenorphine via telehealth depends on federal DEA rules, your state’s telehealth laws, your provider type (MD vs NP), and the state where your patient is located. Miss any one of these compliance pieces and you could face licensing issues or worse.

Let’s cut through the confusion. This guide breaks down exactly what general psychiatry providers need to know about telehealth prescribing in 2026—covering current federal rules, upcoming DEA changes, state-by-state variations, and what it means for your practice.

The Current State of Play: Federal DEA Rules Through 2026

The Ryan Haight Act (2008) technically requires an in-person medical evaluation before prescribing controlled substances via the internet. For years, this made routine telepsychiatry prescribing of stimulants or benzos legally questionable—until COVID changed everything.

When the pandemic hit in March 2020, federal agencies suspended the in-person exam requirement under public health emergency authority. Psychiatrists and PMHNPs could suddenly prescribe Schedule II–V controlled medications to new patients after a telehealth video evaluation, with no prior in-person visit needed. This flexibility proved critical for mental health access and has been repeatedly extended.

As of January 2, 2026, the DEA and HHS announced a fourth extension of these telehealth prescribing flexibilities through December 31, 2026. This means you can continue prescribing controlled substances via telehealth without an initial in-person exam, as long as you conduct a proper evaluation using real-time audio-video technology and the prescription is for a legitimate medical purpose.

What This Means for Your Practice Today:

• New patients never seen in person: You can initiate treatment with Schedule II stimulants (Adderall, Ritalin) or other controlled medications after a thorough telehealth evaluation by video.
• Existing patients: If a patient has ever been seen in person by you or any provider in your practice, there’s no federal restriction on telehealth prescribing for that patient—this has always been allowed.
• Technology requirements: Use interactive, real-time audio-video communication. Telephone-only consultations generally don’t qualify under the temporary rule (with the exception of buprenorphine for opioid use disorder, where audio-only is explicitly permitted for initial prescribing through the 6-month rule discussed below).
• Documentation standards: Document your telehealth evaluation as thoroughly as you would an in-person visit—history, mental status exam, differential diagnosis, treatment rationale. The standard of care doesn’t change just because it’s virtual.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: DEA’s Proposed Permanent Telemedicine Rules

The temporary extension buys time, but permanent rules are coming. In January 2025, the DEA proposed three significant rule changes that will reshape telehealth prescribing:

1. Buprenorphine Expansion (6-Month Rule)

The DEA proposed allowing providers to prescribe buprenorphine for opioid use disorder via telehealth—including audio-only—for up to 180 days (6 months) before requiring an in-person visit. After that initial period, an in-person evaluation would be needed to continue treatment.

Why this matters for psychiatrists: If you treat patients with opioid use disorder, this formalizes your ability to initiate MAT remotely and sustain it for half a year. Combined with the elimination of the X-waiver in 2023 (any DEA-registered provider can now prescribe buprenorphine without special registration), this opens the door for more psychiatrists to treat addiction via telehealth.

2. Special Telemedicine Registration for Schedule II Prescribing

This is the big one. The DEA proposed creating a new ‘Special Telemedicine Registration’ that would allow certain providers to prescribe controlled substances—including Schedule II—to new patients via telehealth without any in-person exam requirement.

For Schedule III–V medications: Any qualified prescriber could obtain this registration.

For Schedule II medications (stimulants, some opioids): The DEA is initially limiting eligibility to specific specialties, and board-certified psychiatrists are explicitly included. Other eligible specialties include hospice/palliative care physicians, long-term care facility doctors, and pediatricians (for specific medications).

What this means: If finalized as proposed, a psychiatrist with this special registration could evaluate a patient entirely via telehealth and prescribe Adderall for ADHD with no in-person visit ever required—a permanent version of what’s temporarily allowed now. Psychiatric NPs would likely be eligible for Schedule III–V (including many anxiety medications), but Schedule II authority for NPs via this pathway is unclear and may depend on state scope-of-practice rules.

The catch? Telehealth platforms themselves would be required to register with the DEA for the first time, and providers would need to comply with a proposed national Prescription Drug Monitoring Program (PDMP) to track controlled prescriptions across state lines. Expect more administrative requirements, but also more regulatory clarity.

3. VA Continuity of Care Rule

A third rule allows VA providers to prescribe controlled substances via telehealth to veterans who had an in-person exam with any VA clinician, treating the entire VA system as one entity for Ryan Haight purposes. This mainly affects federal providers but signals broader regulatory acceptance of telehealth continuity of care.

Timeline and What to Watch

These are proposed rules still under public comment as of early 2026. The DEA is seeking feedback on details like geographic restrictions (must the provider be in the same state as the patient?) and implementation timelines.

Expect finalization sometime in mid-to-late 2026. Until then, the temporary extension remains in effect. As a provider, you should:

• Plan for the possibility of needing a special telemedicine registration for Schedule II prescribing post-2026
• Anticipate using a national PDMP system and possibly annual reporting requirements
• Prepare for platform compliance changes if you work with a telehealth company

State-by-State Prescribing Rules: Where Federal Meets Local Law

Federal DEA rules set the floor, but states can impose stricter requirements—and many do. Here’s what you need to know for the six most important states for telehealth psychiatry:

California: Telehealth-Friendly with Mandatory PDMP Checks

California doesn’t add restrictions beyond federal law for telehealth prescribing. You can establish a patient relationship via video and prescribe controlled substances as long as you meet the standard of care.

State-specific requirements:

• CURES PDMP: You must check California’s prescription monitoring database before prescribing any Schedule II–IV controlled substance to a patient for the first time, then every 4 months for ongoing treatment.
• E-prescribing: 100% e-prescribing required for all prescriptions since January 2022 (rare exceptions only).
• NP practice: Experienced PMHNPs (3+ years in supervised settings) can now practice independently in group practices; by 2026, they’ll be able to open independent practices under California’s phased implementation of AB 890.

Bottom line: California makes it relatively easy to practice telepsychiatry, but you must stay on top of PDMP requirements and ensure full licensure.

Texas: NP Restrictions Create Barriers for Schedule II

Texas allows telemedicine prescribing and explicitly permits mental health evaluations via video without requiring an in-person exam or patient-site presenter. However, nurse practitioners face significant limits.

Critical restrictions:

• NPs cannot prescribe Schedule II medications in outpatient settings—period. The only exceptions are hospital inpatient care (≥24 hours) or hospice. This means a Texas PMHNP cannot prescribe Adderall or other stimulants for ADHD in a routine telehealth practice.
• Physician delegation required: All NPs must practice under physician supervision and delegation agreements in Texas.
• Chronic pain ban: Texas prohibits prescribing controlled substances for chronic pain management via telemedicine without an in-person evaluation (less relevant for general psychiatry but important if you ever co-treat pain).

PDMP requirement: Mandatory Texas PMP check before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol.

Practical impact: If you’re running a telepsychiatry practice in Texas, you need psychiatrists (MDs/DOs) to handle any Schedule II prescribing. NPs can manage most anxiety medications and sleep aids (Schedule III–IV), but any ADHD patient will require physician involvement.

Florida: Psychiatric Exception Saves the Day

Florida has a strict general rule against prescribing Schedule II controlled substances via telehealth—with a critical carve-out that benefits psychiatrists.

The rule: Schedule II medications cannot be prescribed via telehealth unless for one of four purposes:

1. Psychiatric disorder treatment
2. Inpatient hospital care
3. Hospice care
4. Nursing home residents

What this means for psychiatry: You can prescribe Adderall for ADHD or other psychiatric Schedule II medications via telehealth because ADHD is a psychiatric condition. You cannot prescribe opioids for pain management via telehealth (not typically within psychiatry scope anyway).

Additional Florida requirements:

• Out-of-state telehealth registration: Florida allows out-of-state providers to register as telehealth practitioners without full Florida licensure, but they still must follow Florida’s prescribing rules.
• PDMP mandatory: Check Florida’s E-FORCSE database before prescribing any controlled substance to patients ≥16 years old.
• E-prescribing required since 2021.
• NP restrictions: Psychiatric NPs in Florida must have physician supervision (collaborative agreement). No independent practice for psych NPs.

Document the indication: Always clearly document that Schedule II prescriptions are for psychiatric treatment to stay within the legal exception.

New York: Independent NPs and Strict PDMP Rules

New York modernized its NP scope-of-practice laws in 2022, allowing experienced PMHNPs to practice independently after accumulating 3,600 clinical hours.

Key points:

• Full practice for experienced NPs: NPs with >3,600 hours can evaluate, diagnose, and prescribe (including controlled substances) without physician oversight.
• I-STOP PDMP mandate: You must check New York’s Prescription Monitoring Program before prescribing any Schedule II, III, or IV controlled substance—no exceptions. This is one of the strictest PDMP laws in the country.
• E-prescribing required: All prescriptions (controlled and non-controlled) must be sent electronically since 2016.
• Telehealth standard: Video evaluations can establish a valid patient relationship; no in-person requirement.

Note: New York is not part of the Interstate Medical Licensure Compact, so out-of-state providers must complete full New York licensing to treat NY patients.

Pennsylvania: Reduced Practice and Collaboration Requirements

Pennsylvania doesn’t have a comprehensive telehealth statute yet, but telemedicine is permitted under existing medical board authority.

Regulatory landscape:

• NP collaboration required: PMHNPs must have collaborative agreements with at least one physician (preferably two for prescriptive authority). They can prescribe Schedule II for up to 30 days, Schedule III–IV for up to 90 days.
• PDMP mandate: Check Pennsylvania’s PMP before prescribing opioids or benzodiazepines (Act 191).
• E-prescribing: Required for Schedule II–V since October 2019.
• No special telehealth restrictions: Follow standard of care; video evaluations are acceptable.

Interstate: Pennsylvania joined the IMLC in 2021, making it easier for out-of-state physicians to obtain licenses. NPs still need separate PA licenses (no APRN compact).

Illinois: Full Practice Available with Nuances for Controlled Substances

Illinois offers a pathway to full practice authority for experienced nurse practitioners but with specific constraints on certain controlled medications.

Key regulations:

• APRN Full Practice Authority (FPA): PMHNPs can obtain independent practice authority after 4,000 hours of clinical experience and 250 hours of additional training. Without FPA, they need physician collaboration.
• Benzodiazepine/Schedule II limits: Even with FPA, NPs must have a physician ‘consultation relationship’ to prescribe benzodiazepines or Schedule II medications, and can only prescribe 30-day supplies at a time. (The exact application to stimulants vs. opioids is somewhat ambiguous, but it’s safest to assume it includes ADHD medications.)
• PDMP required: Check Illinois PMP before prescribing opioids (mandatory) and recommended for other controlled substances.
• E-prescribing: Required for all controlled substances as of January 2023.

Telehealth: Illinois law recognizes telehealth as equivalent to in-person care with no separate prescribing restrictions.

Scope of Practice: Psychiatrist vs. PMHNP Authority

Understanding scope differences is critical for compliance and practice setup:

Psychiatrists (MD/DO):

• Full independent authority in all states for diagnosing and prescribing all controlled substances
• No supervision or collaboration requirements
• Must be licensed in each state where patients are located
• DEA registration required in each practice state

Psychiatric Mental Health Nurse Practitioners:

Authority varies dramatically by state:

Full Practice States (California transition, New York after 3,600 hrs, etc.):

• Can practice independently after meeting experience thresholds
• Full prescriptive authority including controlled substances
• Can join telehealth platforms without physician oversight

Reduced Practice States (Pennsylvania, Illinois without FPA):

• Require collaborative agreements with physicians
• Can prescribe controlled substances under delegation
• May have quantity or duration limits on certain medications

Restricted Practice States (Texas, Florida):

• Must have supervising physicians at all times
• Significant prescribing limitations (Texas: no outpatient Schedule II)
• Cannot practice independently on telehealth platforms

Practical implication for telehealth platforms: A platform operating nationally needs different compliance structures by state. In Texas, you need MDs on staff to handle stimulant prescriptions. In New York or California (post-2026), experienced NPs can operate fully independently.

Compliance Essentials: What Every Provider Must Do

Regardless of state or provider type, these are non-negotiable:

1. PDMP Checks

Every state now requires checking prescription monitoring databases before prescribing controlled substances. Timing and specifics vary:

• California: Before first Schedule II–IV prescription, then every 4 months
• New York: Before every Schedule II–IV prescription
• Texas: Before opioids, benzos, barbiturates, carisoprodol
• Florida: Before any controlled substance for patients ≥16

2. E-Prescribing

Most states now mandate electronic prescribing for controlled substances:

• Use DEA-compliant e-prescribing systems with two-factor authentication
• Paper prescriptions only in rare technical failure or specific exemptions

3. DEA Training Requirement

As of 2023, all DEA registrants must complete 8 hours of training on substance use disorder and appropriate prescribing before DEA renewal (one-time requirement). Exemptions for addiction psychiatrists whose specialty already covers this.

4. Documentation Standards

Telehealth doesn’t lower the bar for documentation:

• Thorough history and mental status examination
• Clear diagnostic rationale
• Treatment plan and patient education documented
• Informed consent for telehealth services
• Regular follow-up schedules for controlled medications

5. State Licensure

You must be licensed in the state where the patient is physically located during the telehealth visit. No exceptions unless you’re providing one-time consultation to another licensed provider (not direct patient care).

The Economics: Why Telehealth Prescribing Matters for Your Practice

Understanding regulations isn’t just about compliance—it’s about practice viability. Here’s the business reality:

Patient acquisition through traditional channels is expensive:

• SEO takes 6–12 months of consistent investment before generating meaningful patient flow
• Google Ads for mental health keywords cost $15–40+ per click, with realistic cost per booked patient of $200–400+ when you factor in conversion rates
• Psychology Today and similar directories charge monthly fees and you compete with hundreds of other providers on the same page
• Total DIY marketing costs including agency fees, ad testing, staff time, and no-shows: typically $200–500+ per acquired patient

For most psychiatrists—especially those starting out or those in restrictive states like Texas where NP limitations require MD involvement—this creates a chicken-and-egg problem. You need patients to afford marketing, but you need marketing to get patients.

Platforms like Klarity Health solve this by using a pay-per-appointment model:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients

Instead of spending $3,000–5,000/month on marketing with uncertain ROI, you pay a standard listing fee only when a qualified patient books with you. That’s guaranteed ROI versus gambling on marketing channels you may not have the expertise or patience to master.

The regulatory knowledge in this article directly impacts your earning potential. If you understand:

• Which states allow independent NP practice (expand your geographic reach)
• Where Schedule II prescribing is most restricted (focus marketing accordingly)
• How to maintain federal and state compliance (avoid costly licensing issues)

…you can build a sustainable telehealth practice that generates consistent patient flow without the traditional overhead and marketing risk.

Frequently Asked Questions

Can I prescribe Adderall to a new patient I’ve never met in person via telehealth in 2026?

Yes, under the current DEA temporary extension through December 31, 2026. You must conduct a proper evaluation via interactive audio-video technology and document it thoroughly. After 2026, you may need a special DEA telemedicine registration depending on final rule implementation.

What happens if the DEA extension expires and new rules aren’t finalized?

The DEA and HHS have consistently extended flexibilities to prevent care disruptions. If there’s a gap, expect another extension. However, providers should prepare for eventual permanent rules requiring either special registration or in-person exams for certain prescribing scenarios.

Do I need to be licensed in every state where I have telehealth patients?

Yes. Telehealth is regulated by where the patient is located, not where you are. You need full licensure (or appropriate telehealth registration like Florida’s) in each state. Interstate compacts (IMLC for physicians) can streamline this process.

Can psychiatric NPs prescribe ADHD medications via telehealth?

It depends entirely on the state. In New York (with experience) or California (transitioning), yes. In Texas, no—NPs cannot prescribe Schedule II in outpatient settings at all. In Illinois with FPA, yes but with consultation requirements. Always check your specific state’s NP scope-of-practice laws.

Is audio-only (telephone) prescribing allowed for controlled substances?

Generally no, except for buprenorphine under the proposed DEA rule allowing audio-only for opioid use disorder treatment. For other controlled substances including stimulants and benzodiazepines, use interactive video to establish the strongest legal and clinical foundation.

Do state telehealth laws override federal DEA rules?

States can be more restrictive than federal law, but not less. You must comply with whichever rule is stricter. For example, even though federal law currently allows telehealth prescribing, Florida’s law adds the requirement that Schedule II must be for psychiatric treatment—both rules apply.

What documentation should I keep for telehealth controlled substance prescribing?

Document as you would for in-person: chief complaint, detailed psychiatric history, mental status exam, differential diagnosis, treatment rationale, risks/benefits discussion, informed consent for telehealth, and PDMP check confirmation. Many states require specific telehealth consent elements.

What This Means for Joining a Telehealth Platform

If you’re considering joining a platform like Klarity Health, understanding these regulations helps you evaluate the opportunity:

What to look for:

• Multi-state licensing support: Does the platform help with licensing in multiple states or operate only where you’re already licensed?
• Compliance infrastructure: Built-in PDMP access, e-prescribing systems, documentation templates that meet state requirements
• Scope-appropriate patient matching: If you’re a PMHNP in Texas, the platform shouldn’t route Schedule II cases to you
• Malpractice coverage: Ensure your coverage extends to telehealth and all states where you’ll see patients

What Klarity Health offers:

• Pre-qualified patient flow so you’re not starting from zero
• Pay-per-appointment model eliminates marketing risk
• Telehealth infrastructure handles the technology compliance burden
• Both insurance and cash-pay patients (insurance typically pays $150-300+ per session for psychiatric follow-ups)

The key value: you can focus on clinical care while the platform handles patient acquisition, technology, and administrative compliance—exactly what most psychiatrists want when expanding their telehealth practice.

The Bottom Line: Regulatory Clarity Enables Practice Growth

Yes, you can prescribe controlled substances via telehealth in 2026—but the regulatory landscape is complex and changing. Here’s what matters most:

1. Current federal rules allow it through end of 2026 under temporary DEA extensions
2. Permanent rules coming will likely require special registration but may actually expand access for qualified psychiatrists
3. State laws vary dramatically—Florida’s psychiatric exception, Texas’s NP restrictions, New York’s PDMP mandates all create different compliance requirements
4. Provider type matters—psychiatrists have uniform authority nationwide; NP scope varies state by state
5. Compliance is non-negotiable—PDMP checks, e-prescribing, proper documentation, and licensure are table stakes

The providers who thrive in telehealth psychiatry are those who:

• Stay informed on regulatory changes (subscribe to DEA updates, follow your state medical board)
• Maintain meticulous documentation
• Understand their scope and limitations
• Choose practice models (like Klarity’s platform approach) that provide compliant infrastructure and patient flow without requiring massive marketing investment

Telehealth isn’t going away. The demand for psychiatric care far exceeds supply, and patients increasingly expect virtual access. Providers who master the regulatory framework can build thriving practices while improving access to mental health care.

Ready to expand your telehealth practice with a platform that handles patient acquisition and compliance infrastructure? Klarity Health offers psychiatrists and qualified PMHNPs the opportunity to see pre-matched patients, control their schedules, and earn competitive rates—all while staying compliant with federal and state telehealth prescribing regulations. Explore how Klarity can help you grow your practice without the traditional marketing investment and administrative burden.

References

1. U.S. Department of Health and Human Services. (January 2, 2026). HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026. Retrieved from https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration. (January 16, 2025). DEA Announces Three New Telemedicine Rules to Continue Open Access to Medications. Retrieved from https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Florida Legislature. (2025). Florida Statutes §456.47: Use of Telehealth to Provide Services. Retrieved from http://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

4. Akerman LLP. (March 2023). Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth. Retrieved from https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html

5. Substance Abuse and Mental Health Services Administration. (2023). Removal of DATA Waiver (X-Waiver) Requirement. Retrieved from https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices